Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: A SEER population-based study
- PMID: 26999400
- DOI: 10.1016/j.canep.2016.02.011
Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: A SEER population-based study
Abstract
Background: While differences in CPM use between White and Black patients are well known, it is not clear whether CPM use differs by estrogen/progesterone receptor (ER/PR) status of tumors and whether racial/ethnic differences in the use are affected by ER/PR status, which varies between racial groups. The purpose of this study was to investigate whether CPM usage differs by racial/ethnic group and ER/PR status among patients in the Surveillance, Epidemiology, and End Results (SEER) data.
Methods: The study subjects were women with histologically confirmed unilateral breast cancer who underwent breast surgery between 1998 and 2011. Age-adjusted CPM use as a proportion of all surgically treated patients or all patients who had mastectomy was analyzed by racial/ethnic group, tumor behavior, and ER/PR status. Temporal trends in age-adjusted CPM use were presented by ER/PR status and racial/ethnic group.
Results: The analyses stratified by ER/PR status showed significant racial/ethnic differences in age-adjusted CPM use with non-Hispanic White and non-Hispanic Asian/Pacific Islander (API) patients having the most and least CPM use. Age-adjusted CPM use was significantly higher for ER+/PR+ tumors than ER-/PR- ones for each race/ethnicity group among patients with mastectomy. However, among patients with any breast surgeries, the only difference was a higher proportion of CPM use for ER-/PR- tumors (8.6%) than ER+/PR+ tumors (8.0%) in non-Hispanic Whites. CPM use has increased over time in all racial/ethnic groups despite ER/PR status.
Conclusion: CPM usage was lower not only in non-Hispanic Blacks, but also in non-Hispanic API and Hispanic patients compared to non-Hispanic White patients. CPM usage tended to be higher for ER+/PR+ tumors, but the results varied when different denominators (all mastectomies vs. all breast surgeries) were used.
Keywords: Contralateral prophylactic mastectomy; Ethnicity; Hormone receptor; Race; SEER.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups.Cancer. 2001 Jul 1;92(1):37-45. doi: 10.1002/1097-0142(20010701)92:1<37::aid-cncr1289>3.0.co;2-f. Cancer. 2001. PMID: 11443607
-
Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.Cancer Causes Control. 2014 Aug;25(8):959-68. doi: 10.1007/s10552-014-0395-1. Epub 2014 May 17. Cancer Causes Control. 2014. PMID: 24839049 Free PMC article.
-
Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.JAMA Netw Open. 2020 Oct 1;3(10):e2020303. doi: 10.1001/jamanetworkopen.2020.20303. JAMA Netw Open. 2020. PMID: 33074325 Free PMC article.
-
Contralateral Prophylactic Mastectomy and Breast Cancer: Clinical and Psychosocial Outcomes [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2018 Oct. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2018 Oct. PMID: 36996270 Free Books & Documents. Review.
-
Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors.Oncologist. 2023 Feb 8;28(2):116-122. doi: 10.1093/oncolo/oyac239. Oncologist. 2023. PMID: 36495151 Free PMC article. Review.
Cited by
-
Trends in utilization of contralateral prophylactic mastectomy among different age, racial and ethnic groups.Gland Surg. 2023 Sep 25;12(9):1224-1232. doi: 10.21037/gs-22-759. Epub 2023 Sep 18. Gland Surg. 2023. PMID: 37842536 Free PMC article.
-
The impact of coding germline variants on contralateral breast cancer risk and survival.Am J Hum Genet. 2023 Mar 2;110(3):475-486. doi: 10.1016/j.ajhg.2023.02.003. Epub 2023 Feb 23. Am J Hum Genet. 2023. PMID: 36827971 Free PMC article.
-
Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences.Breast J. 2022 Dec 31;2022:1447545. doi: 10.1155/2022/1447545. eCollection 2022. Breast J. 2022. PMID: 36685664 Free PMC article.
-
Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2. Cancer Cell Int. 2021. PMID: 34563200 Free PMC article. Review.
-
Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women.J Racial Ethn Health Disparities. 2021 Feb;8(1):147-156. doi: 10.1007/s40615-020-00766-y. Epub 2020 May 8. J Racial Ethn Health Disparities. 2021. PMID: 32385849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials